Molycorp ( MCP) upgraded at Dahlman from Hold to Buy, Dahlman Rose said. $14 price target. Mountain Pass should deliver a large production ramp. Myriad Genetics ( MYGN) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $32 price target. Company can continue to diversify and expand its business. United Therapeutics ( UTHR) downgraded at JP Morgan from Neutral to Underweight, JP Morgan said. $40 price target. Oral Remodulin received a negative ruling from the FDA. United Therapeutics downgraded at BMO from Outperform to Market Perform, BMO Capital said. $50 price target. New uncertainty around oral treprostinil. Whirlpool ( WHR) upgraded at Goldman from Sell to Buy, Goldman Sachs said. $110 price target. Prices have firmed in Latin America.
STOCK COMMENTS / EPS CHANGES
Apple ( AAPL) estimates, target raised at Canaccord. Shares of AAPL now seen reaching $800, according to Canaccord Genuity said. Estimates also increased, given the new product launches. Buy rating. Altera ( ALTR) estimates, target reduced at BMO. ALTR estimates were cut through 2013, BMO Capital said. Company is seeing lower sales. Outperform rating and new $38 price target. Amgen ( AMGN) estimates, target increased at BMO. AMGN estimates were raised through 2013, BMO Capital said. Company is cutting costs and buying back more stock. Market Perform rating and new $83 price target. Activision Blizzard ( ATVI) added to US Focus List at Credit Suisse. Company can expand its margins over the coming quarters. Broadcom ( BRCM) estimates, target cut at Credit Suisse. Shares of BRCM now seen reaching $45, according to Credit Suisse. Estimates also reduced, as the company is seeing lower sales. Outperform rating. Centene ( CNC) numbers raised at Oppenheimer. Shares of CNC now seen reaching $48, Oppenheimer said. Estimates also raised on third quarter earnings. Outperform rating. Coach ( COH) numbers raised at UBS. Shares of COH now seen reaching $58, UBS said. Estimates also increased as F1Q trends improve. Neutral rating. DuPont ( DD) numbers cut at UBS. Shares of DD now seen reaching $52, UBS said. Estimates also lowered on material 3Q EPS miss. Neutral rating. Gilead ( GILD) estimates, target boosted at Credit Suisse. Shares of GILD now seen reaching $65, according to Credit Suisse. Estimates also upped, given higher product sales. Neutral rating. Gilead Sciences numbers raised at Jefferies. Shares of GILD now seen reaching $59, Jefferies said. Estimates also raised on HCV pipeline. Hold rating. Hartford Financial ( HIG) added to US Focus List at Credit Suisse. HIG was added to the US focus list, according to Credit Suisse. See upside to capital return expectations. Kansas City Southern ( KSU) added to US Focus List at Credit Suisse. KSU was placed on the US focus list, Credit Suisse said. Company can continue to grow faster than consensus expectations. 3M ( MMM) estimates trimmed at UBS through 2013, UBS said. 3Q outlook weaker than expected. Buy rating and $100 price target. Netflix ( NFLX) numbers lowered at Oppenheimer. Shares of NFLX now seen reaching $80, Oppenheimer said. Estimates also lowered on weak subs and guidance. Outperform rating. Netflix estimates, target cut at BofA/Merrill. Shares of NFLX now seen reaching $60, according to Bank of America/Merrill Lynch said. International segment will likely continue to lose money for the next few years. Underperform rating. Netflix target cut at Citigroup. NFLX target lowered to $100, Citigroup said. Q3 miss, but willing to look through forecasting errors. Buy rating. Norfolk Southern ( NSC) numbers lowered at Sterne Agee. Shares of NSC now seen reaching $81, according to Sterne Agee. Estimates also cut, given a reduced coal outlook. Buy rating. Travelers ( TRV) estimates, target increased at Sterne Agee. TRV estimates were raised through 2014, Sterne Agee said. Company is seeing a higher reserve release and lower loss ratio. Neutral rating and new $77 price target.